香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損 失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券的邀請或要約。 （ 於百慕達註冊成立之有限公司） （股份代號：00858） 完成根據一般授權發行新股份 董事會欣然宣佈，認購協議I、認購協議II及認購協議III內載列的所有先決條件已獲達成， 而完成I、完成II及完成III均已於二零二五年九月十日落實。因此，合共160,000,000股新股 份（ 統稱「該等認購股份」）已於二零二五年九月十日按每股認購股份0.097港元配發及發行， 其 中 (i) 30,000,000 股 新 股 份 已 發 行 予 認 購 方 I 、 20,000,000 股 新 股 份 已 發 行 予 認 購 方 I I 及 110,000,000股新股份已發行予認購方III（ 統稱「完成」）。 – 1 – 對本公司股權架構的影響 下表顯示(i)緊接完成前；及(ii)緊隨完成後及於本公告日期的股權架構： 完成根據一般授權發行新股份 ...

Core Viewpoint - The health industry in China is rapidly transforming under the "Healthy China 2030" strategy, presenting significant opportunities for multinational companies like Nu Skin to align their strategies with national health goals and consumer needs [1][6]. Group 1: Long-term Commitment and Strategic Development - Nu Skin views China as a strategic market and innovation hub, emphasizing its long-term commitment to the region [3]. - Recent interactions with local government, such as a meeting with the Shanghai Municipal Commission of Commerce, highlight the company's collaborative approach to leveraging consumption upgrades and promoting high-quality industrial development [4]. - The company plans to increase investments in Shanghai, launching new products and services tailored to local market demands [4]. Group 2: Capacity and Talent Development - Nu Skin has invested approximately 360 million RMB in the second phase of its Greater China Innovation Headquarters, enhancing production efficiency through advanced automation [4]. - The company is focused on talent development, particularly expanding its "Nutrition Health Consultant" program to cultivate skilled professionals in health management [5]. - Nu Skin is also fostering partnerships with local enterprises to integrate global technology with local needs [5]. Group 3: Technological Innovation for Health - Nu Skin is committed to advancing health through technology, aligning with national priorities such as metabolic disease prevention and cognitive health intervention [6]. - The company is shifting from one-size-fits-all products to personalized health solutions, utilizing cutting-edge technologies like gene expression science and AI [6][8]. - Upcoming innovations include the TRME body management plan and the PRYSM iO hyperspectral scanner, aimed at improving metabolic health and sleep quality [7]. Group 4: Digital Transformation and Sustainable Development - Digital transformation is a key pillar for Nu Skin, enhancing operational efficiency and enabling personalized consumer services [9]. - The company has partnered with Alibaba Cloud since 2017 to drive its digital strategy, exemplified by the launch of the Vera skin assessment system [9]. - Nu Skin is committed to sustainability, integrating environmental, social, and governance (ESG) principles into its operations and emphasizing the importance of ecological health alongside human health [9]. Group 5: Future Outlook - Looking ahead, Nu Skin aims to deepen local innovation, expand production capacity, and upgrade digital services in response to the "Healthy China 2030" strategy [10]. - The company's practices serve as a model for how multinational corporations can align with China's health strategy and contribute to industrial upgrades [10].

Core Viewpoint - The "Run BA 2025 National Homeowner Basketball League" initiated by China Resources Land aims to promote community fitness and align with national health strategies, showcasing the company's commitment to creating better living environments and community services [1][3][13]. Group 1: Event Overview - The event concluded successfully with 14 teams competing, and Chengdu's team emerged as the champion [1]. - The league covered 48 cities and 196 communities, hosting over 500 matches and attracting approximately 24,500 homeowners [3][4]. Group 2: Strategic Implementation and Innovation - The event exemplifies a community sports model that integrates government guidance, corporate support, and homeowner participation, addressing the challenge of limited sports facilities and organizations at the grassroots level [4][5]. - The initiative aligns with the "Healthy China 2030" and "Sports Power" strategies, effectively implementing national policies at the community level [3][13]. Group 3: Community Engagement and Feedback - Participants expressed appreciation for the platform provided by China Resources Land, highlighting the event as a valuable opportunity for community interaction and emotional connection [5][11]. - The event received positive feedback from industry professionals, noting its organization and atmosphere comparable to professional leagues [5]. Group 4: Long-term Community Development - The "Run BA 2025" event is part of a broader community service initiative, "Run Neighbor," which focuses on enhancing community engagement through various activities and services [6][8]. - The initiative has built a network of over 610,000 clients and organized more than 36,000 events, fostering a vibrant community ecosystem [8]. Group 5: Future Plans and Sustainability - China Resources Land plans to continue promoting health and fitness through a series of community events, reinforcing its commitment to the "Healthy China" strategy [14]. - The company aims to enhance living quality and community cohesion, responding to the public's desire for better living conditions [13].

Group 1: Financial Performance - The company achieved a revenue of CNY 2.504 billion in the first half of 2025, representing a year-on-year growth of 15.52% [3] - The net profit attributable to shareholders reached CNY 104 million, a significant increase of 42.17% compared to the previous year [3] - The net profit excluding non-recurring gains and losses was CNY 101 million, reflecting a growth of 43.28% year-on-year [3] Group 2: Strategic Initiatives - The company implemented the "1234 strategy," focusing on one core area in pharmaceutical terminals and two directions: product matrix and pharmacy terminals [3] - The management emphasized high-quality development through multi-dimensional layout and systematic optimization, leading to continuous upgrades in industrial structure [3] - The company is shifting from traditional pharmaceutical retail to a comprehensive health service model, enhancing its competitive edge [3] Group 3: Market Challenges - The overall growth rate in the pharmaceutical retail industry has slowed down, with increased competition leading to a decrease in customer traffic and average transaction value [4] - Changes in healthcare policies and the rise of new retail channels have diverted customer traffic away from traditional pharmacies [4] - The number of pharmacies in the market has exceeded 700,000, intensifying competition and pressuring operational efficiency [4] Group 4: Future Outlook - The company plans to expand its store network, having opened 529 new stores in the reporting period, including 51 self-built and 478 acquired stores [8] - The management anticipates long-term growth opportunities driven by an aging population and increasing health demands, particularly in chronic disease management [9] - The company aims to enhance its service value and market position by focusing on product innovation and differentiated services [10] Group 5: Integration and Expansion Strategy - The management is adopting a cautious integration strategy, focusing on developing franchise operations and member business models [6] - The company is looking to make small-scale acquisitions to strengthen its market presence rather than pursuing large-scale expansions [6] - The establishment of a dedicated commercial insurance department aims to integrate health insurance with pharmacy services, enhancing customer experience [7]

Core Viewpoint - The Ministry of Industry and Information Technology and the National Medical Products Administration have announced the second batch of selected units for the innovative task of biomedical materials, with Aojing Medical (688613.SH) leading the "degradable semi-hydrated calcium sulfate" project team, highlighting the company's role in addressing the domestic challenges in high-end bone repair materials [1][2]. Industry Overview - Biomedical materials are referred to as the "chips of medical devices" and are crucial for the localization of high-end medical equipment. Currently, over 60% of the high-end bone repair materials market in China is dominated by imported products, leading to high costs and clinical standard monopolization by foreign companies [1][2]. - The degradable semi-hydrated calcium sulfate is a revolutionary material in bone defect repair, offering advantages such as good biocompatibility, self-curing properties, and adaptability to complex bone defects. However, the core technical challenge lies in maintaining a dynamic balance between degradation and bone regeneration [1][3]. Company Insights - Aojing Medical is recognized as a leading enterprise in the field of mineralized collagen bone repair materials, with a strong commitment to long-term R&D investment and a multidisciplinary research team. The company has accumulated significant technical reserves in key areas such as high-end regenerative medical materials and advanced manufacturing processes [2][3]. - The successful selection in the "revealing the list" initiative signifies Aojing Medical's leadership in the domestic high-end bone repair materials sector. The company aims to collaborate with universities and hospitals to tackle key technical challenges and streamline clinical standard development, thereby enhancing its integrated industry chain from material research to clinical application [3][4]. Market Potential - Under the guidance of the "Healthy China 2030" strategy, the biomedical materials industry is entering a golden development period. According to Frost & Sullivan, the market size for bone repair materials in China is expected to exceed 35 billion yuan by 2030, with the localization rate likely surpassing 70%. The proportion of degradable materials is projected to increase from the current 15% to 40% [3].

Core Viewpoint - Yiling Pharmaceutical has demonstrated strong resilience with a return to double-digit profit growth in the first half of 2025, achieving a net profit of 669 million yuan, a year-on-year increase of 26.03% [1] Product Dimension - Yiling Pharmaceutical has established a diversified pharmaceutical health industry structure, driven by three main sectors: patented traditional Chinese medicine, chemical drugs, and health industry [2] - The patented traditional Chinese medicine segment remains the profit cornerstone, contributing 1.963 billion yuan in revenue, accounting for 48.6% of total revenue, with a gross margin of 65.54% [2] - The chemical drug business is crucial for international market expansion, with significant progress in the development of innovative drugs and a well-structured product pipeline [2] - The health industry aligns with the "Healthy China 2030" strategy, focusing on modern health needs and creating a unique health product system [3] Theoretical Dimension - The theory of "Luo Disease" serves as a foundational pillar for Yiling Pharmaceutical's product development and is a core competitive advantage [4] - The company has developed numerous innovative traditional Chinese medicines under this theoretical framework, enhancing its academic standing and market competitiveness [4] R&D Dimension - Yiling Pharmaceutical invested 399 million yuan in R&D in the first half of 2025, representing 9.87% of its revenue, positioning it at a leading level within the industry [6] - The company has established various innovation platforms and a comprehensive drug integration innovation technology system to support future R&D efforts [6][7] - The company holds 870 valid patents, including 511 invention patents, which will bolster its future product offerings and market competitiveness [8]

Core Viewpoint - The company has demonstrated steady growth in revenue and net profit in the first half of 2025, driven by a clear product strategy, robust channel expansion, and continuous R&D investment, solidifying its leading position in the vitamin and mineral supplement sector while expanding into new health fields such as probiotics and medical aesthetics [1][4] Financial Performance - In the first half of 2025, the company achieved operating revenue of 462 million yuan, a year-on-year increase of 16.37% - The net profit attributable to shareholders reached 82.41 million yuan, reflecting a year-on-year growth of 6.65% [1] Market Opportunities - The "Healthy China 2030" initiative and rising public health awareness have created significant market potential for over-the-counter drugs and dietary supplements - The probiotic market in China surpassed 100 billion yuan in 2022, growing at an annual rate of 11%-12%, with projections nearing 200 billion yuan by 2028 [2] R&D and Innovation - The company invested 16.27 million yuan in R&D in the first half of 2025, accounting for 3.52% of its operating revenue - Progress was made in various sectors, particularly in probiotics, with several patented high-activity strains entering clinical trials for conditions like polycystic ovary syndrome and infant diarrhea [2] Production and Quality Control - The company has enhanced production efficiency and product quality through lean, automated, and information-driven integration - Successful resumption of production for Lingzhi capsules and ongoing technological improvements in production lines demonstrate strong organizational and quality control capabilities [3] Channel Strategy - The company employs a "multi-channel ecosystem" strategy, driving growth through both online and offline channels - It has expanded its reach through a network of distributors and e-commerce platforms, while also exploring overseas markets [3] Strategic Acquisitions and Brand Development - The company completed the acquisition of Minsheng Zhongke (Shandong), further integrating resources in the probiotic business - It launched a professional medical aesthetics brand, "Jisuran," to explore innovative models in the health sector [3] Cash Flow and Financial Health - The net cash flow from operating activities increased by 37.89% year-on-year, attributed to improved inventory management - The company is well-positioned financially to support future R&D, capacity expansion, and market development [4]

Core Viewpoint - The selection of Chen Shaoliang as a candidate for the Chinese Academy of Engineering highlights the growing recognition of Chinese medical professionals in the field of cardiovascular intervention, reflecting the country's emphasis on original medical innovations and high-end medical device localization [1][5]. Group 1: Candidate Selection - The Chinese Academy of Engineering announced a total of 660 valid candidates for the 2025 academician election, with 91 candidates from the Medical and Health Sciences Division [1]. Group 2: Professional Achievements - Chen Shaoliang has made significant contributions to clinical, research, and educational work in cardiology, holding important academic positions in various prestigious organizations such as the American College of Cardiology (ACC) and the European Society of Cardiology (ESC) [3]. - He has published over 300 SCI-indexed papers and has been recognized as one of the most cited scholars in the Chinese cardiovascular field, with some papers cited over a thousand times [4]. Group 3: Innovations and Contributions - Chen's innovative techniques, such as the "DK CRUSH" method for treating coronary bifurcation lesions, have gained international recognition, being included in global guidelines by the European Society of Cardiology [3][4]. - His work on the percutaneous pulmonary artery denervation (PADN) technique was incorporated into the ESC/ERS guidelines for pulmonary hypertension, marking a significant achievement for Chinese medical innovation [4]. Group 4: Alignment with National Policies - Chen's achievements align with national strategies like "Healthy China 2030" and "Technological Self-Reliance," showcasing a complete innovation path from clinical needs to international guideline recognition and industrial transformation [5]. - His selection as a candidate not only acknowledges his personal contributions but also reflects the rising global influence of Chinese medical innovations [5].

Core Viewpoint - The "Run BA 2025 National Homeowner Basketball League" initiated by China Resources Land aims to promote community sports and align with national health strategies, showcasing the company's commitment to creating better living environments and community services [1][6][24]. Group 1: Event Overview - The event took place on August 24 at Chengdu Dong'an Lake Sports Park, concluding with the Chengdu Phoenix City Sun team winning the championship [1]. - The league involved 14 cities, over 500 matches, and approximately 24,500 participants, effectively implementing national health strategies at the community level [7][20]. Group 2: Innovative Community Sports Model - The league adopted an innovative model of "government guidance, corporate platform, homeowner co-creation, and multi-industry collaboration" to enhance community sports participation [8]. - The initiative addressed grassroots challenges such as lack of venues and organization for sports activities, making fitness more accessible to homeowners [8]. Group 3: Community Engagement and Feedback - Participants and spectators praised the event for fostering community connections and providing a platform for interaction among homeowners [9]. - The event was recognized for its professional organization, with comparisons made to high-level basketball leagues [9]. Group 4: Brand and Resource Integration - The event served as a platform for deep collaboration among various business units under China Resources, enhancing brand synergy and community engagement [12]. - The league's marketing strategies included live broadcasts and interactive online campaigns, significantly increasing visibility and engagement [14][15]. Group 5: Long-term Vision and Future Initiatives - The company aims to continue promoting community health and engagement through initiatives like the "Healthy China" strategy, with plans for ongoing sports events across over 2,000 communities [25]. - The president of China Resources Land emphasized the importance of creating a sense of belonging and community through these initiatives, aligning with the company's long-term goals [24].

Core Insights - The company reported a revenue of 843 million yuan, representing a year-on-year increase of 20.46% [1] - The net profit attributable to shareholders was 51.3 million yuan, showing a year-on-year decline of 39.46% [1] - Research and development investment increased by 59.16%, with an R&D intensity of 15% [1] Business Strategy - The company is leveraging the "Healthy China 2030" strategy, focusing on breakthroughs in high-end medical imaging equipment technology and global market expansion [1] - In response to global supply chain adjustments and structural upgrades in the industry, the company is enhancing its R&D system, deepening market layout, and optimizing industrial collaboration [1] Technological Advancements - The company has made significant technological progress, with one-third of its workforce dedicated to R&D, focusing on high-end CT and self-developed core components [1] - The world's first helium-free MR has achieved mass production, eliminating the "bottleneck" risk associated with helium supply [1] - The quantum DSA, utilizing a self-controlled rare earth detector, is leading the way in low-dose angiography [1] - As of June 2025, the company has been granted 243 authorized intellectual property rights, which are widely applied in its main business [1]